Drugs / MK-3120
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07232602 | Feb 2026 → Jul 2031 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07222488 | Dec 2025 → Feb 2029 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06818643 | Mar 2025 → Mar 2031 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05562830 | Nov 2022 → Feb 2029 expected | urothelial carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05562830 ↗ |
| Route | Intravenous | “Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.” NCT05562830 ↗ |